CabaCy—evaluating Cabazitaxel efficaCy by patterns of treatment and disease in metastatic castration resistant prostate cancer (mCRPC) patients: a 5 years, “Real Life”, mono-institutional experience

Authors:

Abstract
Background: Since 2004, Docetaxel represents the standard 1st-line chemotherapy for mCRPC patients . Cabazitaxel shows an OS benefit in patients progressing during and after Docetaxel, including those refractory to Docetaxel. It also retains activity in patients progressing with new androgen receptor-targeted agents (ART) such as abiraterone or enzalutamide. A large early access program showed that Cabazitaexl has a manageable safety profile, without evidence of cumulative toxicity. We aimed at evaluating the activity of Cabazitaxel according to therapy line and disease burden.